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We have previously demonstrated a high propensity for enhancement of virus replication and disease resulting from
experimental immunization of ponies with a baculovirus recombinant envelope (rgp90) vaccine from equine infectious anemia
virus (EIAV). The current studies were undertaken to examine the correlation between the observed in vivo vaccine
enhancement and in vitro assays for antibody-dependent enhancement (ADE) of EIAV replication. Toward this goal an
optimized EIAV in vitro enhancement assay was developed using primary equine macrophage cells and used to evaluate the
enhancement properties of immune serum taken from rgp90 immunized ponies that displayed various levels of vaccine
enhancement after experimental challenge with EIAV. For comparison, we analyzed in parallel immune serum samples from
a group of ponies immunized with a viral envelope subunit vaccine (LL-gp) that produced sterile protection from EIAV
challenge. The results of these assays demonstrated that the rgp90 immune serum had a greater propensity for in vitro
enhancement of EIAV replication than serum from the protected LL-gp immunized ponies; in vitro enhancement levels for the
rgp90 immune sera averaged about 1.5, with a maximum enhancement value of about 2.0. While distinguishing between
immune serum produced by the rgp90 and LL-gp immunizations, the in vitro enhancement assay failed to reliably correlate
with the severity of in vivo enhancement observed among the rgp90 vaccine recipients. Vaccinated ponies that experienced
moderate to no disease signs displayed levels of in vitro enhancement similar to those of ponies that experienced severe
and fatal enhancement of disease after viral challenge. The observed in vitro enhancement was demonstrated to be
dependent on serum immunoglobulin, but independent of complement. These studies demonstrate in the EIAV system that
in vitro ADE assays appear to be relatively insensitive indicators of the severity of in vivo enhancement and that relatively
low levels of in vitro ADE can be associated with severe to fatal enhancement of virus replication and disease in vivo. These
observations suggest that relatively low levels of serum ADE observed in other lentivirus systems, including HIV-1, may have
more profound effects on in vivo virus replication and disease than previously recognized. © 1999 Academic Press
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iINTRODUCTION
The potential for vaccine-induced enhancement of in-
ections by enveloped viruses has been documented in
oth human and veterinary vaccine studies (Burke, 1992;
alsted, 1982; Mascola et al., 1993; Morens, 1994; Por-
erfield, 1986). In the case of AIDS vaccine research,
here has been considerable concern that immunization
ith HIV envelope proteins may increase susceptibility
o infection or exacerbate disease following virus expo-
ure of vaccinated individuals (Bolognesi, 1989; Burke,
992; Cohen, 1994; Mascola et al., 1993). A number of
otential mechanisms have been proposed for immune
nhancement of HIV-1 replication in vivo, mostly related
o activation of humoral and cellular immune responses
Burke, 1992, 1995; Mascola et al., 1993). For example,
onclonal activation of the host immune system can
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416esult in an overall increase in the number of target
ymphocyte and macrophage cells, leading to increased
evels of viral replication. In addition to a larger popula-
ion of target cells, an increase in the cellular activation
tates of the target lymphocytes and macrophage cells
an also result in increased levels of virus replication, as
entiviruses have been shown to replicate more effi-
iently in activated cells (Clements and Zink, 1996; Clem-
nts et al., 1994; Narayan and Clements, 1989; O’Brian et
l., 1995; Stanley et al., 1996). Also, evidence for the
bility of antibody and complement to enhance HIV-1 and
IV infectivity or replication efficiency in vitro has been
stablished in numerous studies. Antibody-dependent
nhancement (ADE) has been shown to operate in vitro
hrough the interaction of immunoglobulin (Ig) and Fc
eceptors (FcRs) alone (Homsy et al., 1989; Takeda et al.,
988) or in combination with CD4 molecules (Connor et
l., 1991; Perno et al., 1990; Takeda and Ennis, 1990;
akeda et al., 1990). Complement-mediated antibody-
ependent enhancement (C9-ADE) has been shown to
nvolve the interaction of both complement and Ig via
omplement receptors (CRs) and CD4 molecules (Lu et
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417EQUINE INFECTIOUS ANEMIA VIRUS ENHANCEMENTl., 1996; Montefiori et al., 1990a,b, 1995, 1996a; Robinson
t al., 1988, 1990a,b, 1991). However, enhancement in the
resence of complement alone has been observed in
ome studies (Robinson et al., 1989).
While the occurrence of ADE in vitro has been well
ocumented for HIV-1, the relevance of the observed in
itro ADE activity to viral infection and disease in vivo
emains to be determined. Limited studies suggest that
he level of in vitro enhancement of HIV-1 infection by
era from HIV-1-infected patients may correlate with the
rogression of disease in vivo (Fust et al., 1994; Homsy et
l., 1990; Toth et al., 1991). In contrast, other studies
eport a lack of correlation between in vitro HIV-1 en-
ancement and disease progression in vivo (Haubrich et
l., 1992; Montefiori et al., 1991, 1996b; Shadduck et al.,
991). To date, the significance of in vitro ADE or C9-ADE
o HIV-1 infections in vivo remains uncertain and contro-
ersial. As with HIV-1, C9-mediated and antibody-depen-
ent enhancement of SIV infections in vitro has been
bserved (Lu et al., 1996; Montefiori et al., 1990a, 1990b,
995, 1996a), but evidence of immune enhancement of
IV infections in vivo is limited (Gardner et al., 1995;
chlienger et al., 1994). Thus, the HIV-1 and SIV enhance-
ent studies similarly reveal in vitro ADE activities in the
bsence of definitive in vivo relevance.
Examples of vaccine-mediated enhancement of infec-
ions in vivo have been documented for several animal
entiviruses, including visna virus, caprine arthritis-en-
ephalitis virus (CAEV), and feline immunodeficiency vi-
us (FIV) (Flynn et al., 1997; Hosie et al., 1992; Lombardi
t al., 1994; McGuire et al., 1986; Nathanson et al., 1981;
ichardson et al., 1997; Siebelink et al., 1995). In these
entivirus systems, however, the observed in vivo vaccine
nhancement has not readily correlated with in vitro ADE
ssays. For example, efforts to accurately reproduce
nhancement of FIV infections in vitro using sera from
ats that were enhanced in vivo have been unsuccessful
Hosie et al., 1992; Richardson et al., 1997). Some in vitro
tudies have demonstrated the ability of serum antibod-
es to visna virus and CAEV envelope proteins to en-
ance virus binding, internalization, and uncoating, but
n increase in the production of virions has not been
bserved (Jolly et al., 1989a, b; Kennedy-Stoskopf and
arayan, 1986). This lack of in vitro assays that reliably
eflect the extent of in vivo enhancement precludes the
evelopment of diagnostic assays for potentially enhanc-
ng immune responses to candidate lentivirus vaccines,
ncluding human AIDS vaccine trials, and inhibits studies
f the mechanisms of vaccine enhancement in vitro.
Equine infectious anemia virus (EIAV) is a macrophage
ropic lentivirus that infects members of the equine spe-
ies worldwide. The EIAV system has been used to study
atural immunologic control of a lentivirus infection and
s a model to evaluate vaccine strategies against lenti-
iruses. In the course of evaluating a variety of experi-
ental vaccines to EIAV, we have observed a remarkable ipectrum of vaccine efficacy ranging from sterile protec-
ion from virus challenge to severe and fatal enhance-
ent of EIAV replication and disease. Vaccines based on
nactivated whole virus (wv) or on purified viral envelope
lycoproteins (LL-gp) elicit sterile protection from homol-
gous EIAV challenge and protection from the develop-
ent of disease following heterologous virus challenge
Issel et al., 1992). In contrast, immunization with a re-
ombinant subunit vaccine consisting of a baculovirus
xpressed envelope SU glycoprotein (rgp90) results in
apid and severe enhancement of clinical disease symp-
oms accompanied by accelerated virus replication in
bout 40% of vaccinated ponies (Raabe et al., 1998a).
ased on the results of these vaccine studies, the EIAV
ystem appears to offer a unique lentivirus system in
hich to examine the mechanisms of vaccine enhance-
ent and to evaluate the accuracy of in vitro assays as
orrelates of in vivo enhancement. Toward these goals,
e describe in this study the development of an in vitro
IAV enhancement assay system using primary equine
acrophage and the use of this assay to determine the
nhancement properties of immune sera from experi-
entally immunized ponies. The correlation of this in
itro activity to enhancement of EIAV disease in vivo is
iscussed and the implications for AIDS vaccine devel-
pment are considered.
RESULTS
Development of an in vitro enhancement assay for
IAV. Many different assay systems and conditions have
een described for the evaluation of in vitro ADE in the
IV and SIV lentivirus systems. Variations in such assays
nclude the use of a number of immortalized cell lines,
rimary macrophage, whole immune serum, purified im-
unoglobulin, monoclonal antibodies, purified comple-
ent, and laboratory-adapted strains of virus as well as
rimary isolates (Homsy et al., 1989; Montefiori et al.,
991; Robinson et al., 1989, 1990b; Shadduck et al., 1991;
akeda et al., 1988). The goal of this study was to deter-
ine how in vitro enhancement assays correlate with
isease progression in vivo; therefore, we sought to
stablish a sensitive, specific, and reproducible in vitro
ssay system to accurately measure enhancement of
IAV replication.
To develop the EIAV in vitro enhancement assay, a
umber of assay parameters were evaluated extensively.
brief summary of the critical assay features determined
rom these analyses follows: (i) Virus strain: The patho-
enic PV strain of EIAV (EIAVPV) used in the in vitro
nhancement assay was the standard virus challenge
train used in our experimental vaccine trials, including
hose resulting in vaccine enhancement. (ii) Virus inoc-
lum: Concentrations of virus ranging from a m.o.i. of
.001 to 10.0 were evaluated. The levels and reproduc-bility of the enhancement obtained with m.o.i. levels of
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418 RAABE, ISSEL, AND MONTELARO.001 to 1.0 were found to be comparable, while m.o.i.
evels above 1.0 resulted in substantially lower enhance-
ent activity under otherwise identical assay conditions.
ased on these preliminary assays, a m.o.i. of 0.1 was
hosen for these studies as maximum levels of enhance-
ent were consistently observed between 5 and 7 dpi.
iii) Target cell: Primary equine macrophages were cho-
en as the target cell in the in vitro ADE assay, as these
ells are the natural target cell for EIAV infection in vivo.
reliminary experiments with equine fibroblastic cell
ines and primary fetal equine kidney (FEK) cells yielded
nly insignificant levels of in vitro enhancement activity,
ndicating the specificity of the enhancement phenom-
nom for the natural macrophage target cells. (iv) Meth-
ds for enhancement quantification: Parameters evalu-
ted for quantifying in vitro enhancement included mea-
urements of the number of infected cells by
mmunofluorescence or PCR techniques and the levels
f virus replication by standard assays of supernatant RT
ctivity or PCR assays of intracellular provirus. The re-
ults of these experiments indicated that the measure-
ent of supernatant RT activity provided the most sen-
itive and reproducible measurement of enhanced virus
eplication in vitro and thus was utilized in the optimized
DE assay. Thus, cell supernatant samples were col-
ected at 3, 5, 7, and 9 dpi and tested for RT activity to
nsure detection of maximum level of virus replication.
v) Comparison to autologous preimmune sera: Our lab-
ratory has previously reported the ability of normal
erum to enhance EIAV virus replication in vitro (Raabe
t al., 1998a), as described for HIV-1 (Wu et al., 1995). To
ccount for this potential source of in vitro enhancement,
e elected to calculate EIAV enhancement levels as the
atios of RT activity produced in the presence of immune
erum to the RT activity derived in the presence of au-
ologous preimmune serum. While this method of calcu-
ation may reduce the absolute level of calculated serum
nhancement activity, we believe that it provides a more
eliable measurement of enhancement due to vaccina-
ion. (vi) Addition of immune serum during incubation of
acrophage cultures: Based on the premise that anti-
ody-dependent enhancement would be amplified dur-
ng multiple rounds of virus replication in the presence of
nhancing antibody, we compared apparent enhance-
ent levels in assays with and without the presence of
est immune serum in the macrophage cultures during
he 7-day incubation period. The results of these studies
learly demonstrated that the continued presence of test
mmune serum in cultures of virus-infected cells yielded
igher levels of virus replication compared to a limited
xposure of the virus inoculum with the test serum only
uring the initial infection procedure. Additional studies
ndicated that a serum dilution of 1:50 yielded the highest
evels of enhancement activity without the complication
f serum cytotoxicity to the target macrophage observed
t lower dilutions of serum. iIn summary, the optimized EIAV in vitro enhancement
ssay system consisted of serial dilutions of fresh im-
une (or preimmune) sera preincubated with EIAVPV vi-
us prior to the infection of equine macrophage. Follow-
ng the removal of the serum–virus mixtures, the cells
ere cultured in fresh medium containing immune or
reimmune sera, and levels of virus replication were
valuated through measurements of RT activity in the cell
upernatants. Levels of virus replication achieved in the
resence of immune sera were then compared to those
chieved in the presence of autologous preimmune sera.
he resulting ratios of virus replication for immune sera
ompared to preimmune sera were reported as en-
ancement indexes, where values greater than 1.0 were
ndicative of enhancement of infectivity, and values less
han 1.0 suggested neutralization.
Using this optimized in vitro enhancement assay, we
nitially evaluated several immune serum samples from
gp90 immunized ponies that experienced marked en-
ancement of disease in vivo following virus challenge.
o closely mimic the immune responses present at the
ime of virus challenge, the immune serum samples were
ollected immediately prior to virus challenge. All sera
ollect at day of challenge (d.o.c.) from rgp90 vaccinated
onies failed to demonstrate detectable neutralizing ac-
ivity in our standard EIAV in vitro neutralization assay
data not shown). Therefore, these sera offered the
nique opportunity to examine in vitro enhancement of
entivirus infectivity in the absence of neutralizing anti-
odies. Figure 1 presents representative data obtained
rom the optimized EIAV ADE assay using test immune
era from rgp90 vaccinated pony 526 that experienced
evere in vivo enhancement after virus challenge (Raabe
t al., 1998a). The data in Fig. 1A summarize the super-
atant RT levels that resulted from EIAV infections in the
resence of serial dilutions of d.o.c. immune serum or of
utologous preimmune serum. These RT data demon-
trate that the levels of virus replication achieved at
elatively low dilutions (,1/500) of d.o.c. immune serum
ere consistently higher than the virus replication ob-
ained in the presence of equivalent dilutions of preim-
une sera. Interestingly, as the serum samples were
iluted further, the levels of virus replication observed in
he presence of the d.o.c. immune serum decreased. In
ontrast to these sequential decreases in virus replica-
ion observed at higher dilutions of the rgp90 immune
erum, virus replication increased with higher dilutions
f preimmune serum. These data clearly demonstrate
hat the rgp90 d.o.c. immune serum specifically pro-
uced an increase in EIAV replication in cultured mac-
ophages and that the level of this enhancement was
nversely proportional to the serum dilution. The obser-
ation of EIAV in vitro enhancement at low dilutions of the
gp90 immune serum is in distinct contrast to previous
tudies with immune serum from cats infected with felinenfectious peritonitis virus (FIPV), HIV-1-infected patients,
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419EQUINE INFECTIOUS ANEMIA VIRUS ENHANCEMENTFIG. 1. Immune serum activities and specifities in the optimized EIAV in vitro enhancement assay. Preimmune and immune sera collected on the
ay of challenge and at 8 weeks postchallenge from rgp90 immunized ponies that experienced enhanced disease were serially diluted and evaluated
n the EIAV in vitro enhancement assay as described under Materials and Methods. (A) Levels of RT activity achieved in cell cultures infected in the
resence of preimmune (open diamonds, broken line) and d.o.c. immune sera (closed diamonds, solid line). (B) Levels of RT activity achieved in cell
ultures infected in the presence of preimmune (open squares, broken line) and postchallenge sera (closed squares, solid line). (C) Enhancement
ndexes calculated from the RT activities shown in A (closed diamonds, solid line) and B (closed squares, solid line). Values greater than 1.0 were
ssociated with enhancement of EIAV replication, while values less than 1.0 indicated suppression of EIAV replication. All data presented are the
verage of at least two independent infections.
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420 RAABE, ISSEL, AND MONTELAROnd SIV-infected monkeys in which maximum ADE levels
ere observed at higher dilutions of the test immune
erum, presumably at dilutions that eliminate intrinsic
erum neutralization activity (Homsy et al., 1990; Monte-
iori et al., 1990b, 1995; Olsen et al., 1992; Takeda and
nnis, 1990). This difference apparently reflects the ab-
ence of serum neutralizing activity in the EIAV gp90
mmune sera.
To test this hypothesis further, and to validate our EIAV
n vitro ADE assay, we next assayed rgp90 immune
erum collected at 8 weeks postchallenge from rgp90
accinated pony 21, which also experienced enhanced
isease (Wang et al., 1994). This postchallenge serum
as shown in our standard in vitro neutralization assay
o have a neutralization end-point titer of about 1:50 (data
ot shown). The data in Fig. 1B summarize the superna-
ant RT levels observed in the presence of dilutions of the
ostchallenge serum compared to serial dilutions of au-
ologous preimmune serum. These data demonstrate
ower levels of virus replication in the presence of post-
hallenge immune serum compared to autologous pre-
mmune serum at dilutions below 1:100, indicating the
eutralization activity contained in this postchallenge
mmune serum. At higher serum dilutions, however, virus
eplication levels were essentially the same in the pres-
nce of the postchallenge immune serum or the preim-
une serum. These data clearly demonstrate that the in
itro assay conditions described here distinguish be-
ween immune serum enhancement and neutralization of
IAV replication, thus, validating the described optimized
nhancement assay.
To compare the activities of d.o.c. and postchallenge
mmune serum in the in vitro ADE assay, we next calcu-
ated the enhancement index from the ratio of the RT
evels produced in the presence of each dilution of im-
une serum compared to the preimmune serum. The
alculated ratios for the d.o.c. and postchallenge im-
une serum samples are summarized in Fig. 1C. These
ata clearly indicate the opposite effects of these serum
amples on virus replication and the effects of serum
ilution on the respective in vitro enhancement and neu-
ralization activities. The d.o.c. serum enhances virus
eplication, and the level of enhancement decreases
ith increased serum dilution; the observed enhance-
ent has a maximum value of about twofold and reaches
n end-point at a dilution of 1:200. In contrast, the post-
hallenge immune serum suppressed virus replication at
ow serum dilutions, with a maximum twofold neutraliza-
ion and an end-point titer of about 1:100.
Taken together, these data demonstrate the capacity
f the in vitro ADE assay to detect serum enhancement
f EIAV replication and to distinguish this activity from
erum neutralization of virus infectivity. Moreover, these
ypes of representative data suggested that immune se-
um samples lacking neutralization activity could be as-
ayed at serum dilutions of 1:5 to achieve maximum mevels of in vitro enhancement and to facilitate evaluation
f large numbers of serum samples.
Role of virus-specific serum antibodies in enhance-
ent of EIAV replication in vitro. Several reports have
escribed in detail the ability of normal human plasma,
eminal fluid, and vaginal secretions lacking virus-spe-
ific antibodies to enhance the replication of HIV-1 in
BMC and monocyte-derived macrophage (MDM) cells
n vitro (Messaoudi et al., 1994; Nara et al., 1994; Spear,
993; Wu et al., 1995). Our laboratory has also reported
he ability of normal horse sera to enhance EIAV infec-
ivity in vitro in a concentration-dependent manner
Raabe et al., 1998b). These reports demonstrate the
bility of undefined serum factors to influence levels of
irus replication in vitro. Therefore, to more critically
valuate the role of virus-specific antibody in enhance-
ent of EIAV replication in vitro, serum Ig was isolated
rom preimmune and d.o.c. immune serum samples from
hree severely enhanced rgp90 I ponies (1-6, 1-7, and 21)
nd evaluated for in vitro enhancement, as described
bove. For comparison, Ig fractions were also isolated
rom 8-week postchallenge immune sera from the same
roup of ponies and compared in parallel for in vitro
ffects on EIAV replication.
Figure 2 summarizes the enhancement index values
btained with Ig isolated from the rgp90 immune sera at
oncentrations equivalent to a 1:5 dilution of the respec-
ive whole serum. The levels of in vitro enhancement
bserved with d.o.c. serum Ig isolated from all three
gp90 immunized ponies were relatively low, but equiv-
lent to those observed with whole sera from those
ame ponies. Serum Ig collected from the same three
gp90 immunized ponies at 8 weeks postchallenge
learly reduced the levels of EIAV replication, as ob-
erved with the respective postchallenge immune serum
amples (data not shown). These data demonstrate the
ole of virus-specific serum antibodies in the observed
erum enhancement of EIAV replication in cultured mac-
ophages, compatible with ADE mechanisms.
Role of complement in the serum enhancement of EIAV
eplication in vitro. Previous studies with HIV-1 and SIV
ave demonstrated the ability of serum complement fac-
ors to enhance virus replication in vitro, both indepen-
ently and in conjunction with virus-specific antibodies
Lu et al., 1996; Montefiori et al., 1990a,b, 1995, 1996a;
obinson et al., 1988, 1990a,b, 1991). Therefore, we next
valuated the role of equine complement in serum en-
ancement of EIAV replication in vitro. For these experi-
ents, fresh and heat-inactivated (56°C for 30 min) pre-
mmune and immune serum samples from a rgp90 im-
unized pony were examined for their effect on EIAV
eplication in vitro (Fig. 3A). Pony 1-5 was chosen for
hese experiments as this pony experienced fatal en-
ancement of disease in vivo. The results of these ex-
eriments indicated similar levels of in vitro enhance-
ent in the presence of either the fresh or the heat-
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421EQUINE INFECTIOUS ANEMIA VIRUS ENHANCEMENTnactivated immune serum samples. Furthermore, the
ddition of complement in the form of fresh normal horse
erum to the heat-inactivated rgp90 immune serum sam-
les failed to change the level of apparent level of in vitro
nhancement (Fig. 3A).
To extend these studies, d.o.c. serum Igs isolated from
hree rgp90 immunized ponies (1-6, 1-7, and 21) were
valuated in the in vitro enhancement assay in the pres-
nce of complement (Fig. 3B). As described for Fig. 2,
erum Ig isolated from these three ponies displayed
elatively low levels of in vitro enhancement despite the
everity of enhancement experienced by these ponies in
ivo. When combined with a 1:5 dilution of fresh normal
orse serum, the levels of in vitro enhancement ob-
erved were similar to those elicited by serum Ig in the
bsence of complement for all three ponies. The results
f these studies demonstrate that the observed en-
ancement of EIAV replication in vitro was not dependent
n complement alone or in combination with virus-spe-
ific antibodies, indicating complement-independent
DE as a primary mechanism of EIAV replication in
acrophage target cells.
Comparison of in vitro enhancement of EIAV infectivity
nd disease severity in vivo. Having optimized and stan-
ardized the in vitro ADE enhancement assay procedures,
e next sought to examine the relationship between levels
FIG. 2. Role of serum immunoglobulin in EIAV enhancement in vitr
ostchallenge immune sera (open diamonds) collected from rgp90-imm
ssay as described under Materials and Methods. All data presentedf immune serum enhancement in vitro and the severity of Lisease enhancement in vivo in experimentally immunized
onies challenged with EIAVPV. For this comparative study,
e selected a panel of d.o.c. immune serum from three
eparate vaccine trials. Four serum samples were taken
rom the baculovirus rgp90 I vaccine trial in which all four
mmunized ponies experienced severe enhancement of
isease after virus challenge (Wang et al., 1994). Nine
erum samples were taken from the baculovirus rgp90 II
rial, in which four rgp90 immunized ponies experienced
nhanced disease signs after virus challenge and five po-
ies experienced moderate to no disease signs (Raabe et
l., 1998a). For comparison to the rgp90 vaccinated ponies,
e also included d.o.c. immune serum samples from four
L-gp immunized ponies that achieved sterile protection
rom virus challenge (Issel et al., 1992; Issel et al., manu-
cript in preparation). Thus, the serum panel from these 17
onies represented a range of vaccine efficacy from severe
nhancement (8 ponies), to lack of protection without en-
ancement (5 ponies), to sterile protection (4 ponies).
All serum samples (at a 1:5 dilution) were evaluated in
our independent assays for their effect on EIAV replica-
ion in vitro, and the average enhancement index calcu-
ated for each serum sample is presented in Fig. 4.
verall, the data indicated that the rgp90 immune sera
ere more likely to enhance the levels of EIAV replication
n vitro than the immune serum samples taken from the
unoglobulins isolated from d.o.c. immune sera (closed squares) and
ponies 1-6, 1-7, and 21 were evaluated in the EIAV in vitro enhancement
average of at least two independent infections.o. ImmL-gp vaccine recipients. Ten of the 13 rgp90 immune
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422 RAABE, ISSEL, AND MONTELAROerum samples enhanced virus replication in vitro, with a
aximum enhancement level of about 2 and an average
nhancement of about 1.3. In contrast, immune sera
ollected from only one of the four LL-gp vaccinated
onies resulted in enhanced levels of virus replication in
itro; the other 3 immune serum samples failed to in-
rease virus replication levels in repeated assays.
While the in vitro enhancement assay was able to
istinguish between the rgp90 and the LL-gp immune
FIG. 3. Role of complement in EIAV enhancement in vitro. (A) Fresh p
n the EIAV in vitro enhancement assay (solid bar) and compared to preim
omplement (dotted bar). Complement-restored heat-inactivated sera w
bility of serum Ig to enhance EIAV infectivity in vitro in the absence (s
re the average of two independent infections.erum samples, it did not differentiate among the rgp90 daccinates with respect to the extent of disease en-
ancement in vivo. The levels of in vitro enhancement
bserved using immune serum samples from the rgp90
mmunized ponies that did not experience enhanced
isease signs (118, 60, 120, 64, and 56) were similar to
hose observed for the eight rgp90 vaccinates that expe-
ienced severe or fatal enhancement of disease after
irus challenge (1-5, 1-6, 1-7, 21, 526, 66, 90, and 65).
hese data indicate that in vitro ADE assays can reliably
ne and immune sera collected at d.o.c. from pony 1-5 were evaluated
and immune sera that had been heated at 56°C for 30 min to inactivate
o evaluated for its enhancing ability in vitro (striped bar). B shows the
r) and in the presence of complement (dotted bar). All data presentedreimmu
mune
as als
olid baistinguish between antibodies elicited by a potentially
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423EQUINE INFECTIOUS ANEMIA VIRUS ENHANCEMENTrotective (LL-gp) and enhancing (rgp90) vaccine. How-
ver, the in vitro ADE levels are insensitive and unreli-
ble as a correlate of the severity of disease enhance-
ent in vivo among the rgp90 vaccine recipients.
DISCUSSION
The potential for immune enhancement by candidate
IDS vaccines remains a concern in the design and
valuation of safety and efficacy trials. In this regard, the
vailability of a reliable and sensitive in vitro assay as a
orrelate of in vivo enhancement would greatly assist the
afety and efficacy evaluations of potential AIDS vac-
ines. Studies in several animal lentivirus systems have
emonstrated the occurrence of in vivo enhancement of
irus replication and disease in experimentally vacci-
ated animals, but to date there have been no reports of
eliable in vitro correlates of in vivo enhancement of
isease in these animal lentivirus systems (Flynn et al.,
997; Hosie et al., 1992; Lombardi et al., 1994; McGuire et
l., 1986; Nathanson et al., 1981; Richardson et al., 1997;
iebelink et al., 1995). In light of the exclusively macro-
hage tropism of EIAV and the severe enhancement of
FIG. 4. Evaluation of immune serum in vitro ADE activity as a correlate
gp90 immunized ponies that experienced enhanced signs of disease
r remained asymptomatic (closed circle) were evaluated in the EIAV i
he rgp90 immune sera were compared to those obtained with seru
hallenge in vivo (open triangles). Data presented are the average ofirus replication and disease that was observed in po- sies immunized with the rgp90 vaccine, the EIAV system
ffered a unique opportunity to evaluate the potential of
n vitro enhancement assays as a correlate for in vivo
nhancement. Thus, the goals of the present studies
ere to develop a reproducible and relevant in vitro
ssay system for EIAV and to evaluate in vitro serum
nhancement of virus replication in cultured target cells
s a correlate of in vivo vaccine enhancement.
To accurately detect a correlation between in vitro and
n vivo enhancement of EIAV, it was imperative that the in
itro assay system utilized be relevant and reliable. While
complete and detailed discussion of all of the optimi-
ations undertaken in this study is beyond the scope of
his report, a number of the more crucial assay param-
ters were discussed under Results to emphasize the
rofound influence of even minor assay variations on
pparent in vitro serum enhancement activity. Following
xtensive experimentation to optimize and standardize
ssay procedures, we were able to develop an assay
sing cultured equine macrophage that reliably detected
oth enhancement and suppression of virus replication
n the presence of test immune serum. This study repre-
V vaccine enhancement in vivo. Immune serum collected at d.o.c. from
squares), experienced moderate signs of disease (closed diamonds),
nhancement assay. The levels of in vitro enhancement obtained with
ected from LL-gp immunized ponies that were protected from virus
ependent infections in MDM cells.of EIA
(closed
n vitro eents the first successful demonstration of in vitro serum
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424 RAABE, ISSEL, AND MONTELAROntibody of EIAV replication, an achievement made pos-
ible by our recent development of equine macrophage
ulture procedures (Raabe et al., 1998b).
Despite our exhaustive efforts to optimize our in vitro
nhancement assay for EIAV in cultured macrophages,
e remained confronted with two potentially trouble-
ome aspects of the assay system, sensitivity and repro-
ucibility. First, we observed maximum in vitro enhance-
ent levels of about 2.0, even in assays of serum sam-
les from rgp90 vaccinated ponies that experienced fatal
nhancement of virus replication and disease. The ma-
ority of the rgp90 serum samples displayed enhance-
ent levels in the range of 1.1–1.6, representing 10–60%
ncreases in virus replication by immune serum com-
ared to preimmune serum samples. A review of in vitro
erum enhancement activities reported for other envel-
ped viruses (Kliks et al., 1989; Olsen et al., 1992) and for
IV and SIV (Mascola et al., 1993) reveals reported en-
ancement values ranging from 0.1- to 10-fold (10 to
000%). In the particular case of HIV-1, reported in vitro
erum enhancement levels obtained in primary cells
Homsy et al., 1990) are similar to the enhancement
evels observed in this study with EIAV, while enhance-
ent levels obtained in lymphocyte cell lines with in-
reased numbers of complement receptors (e.g., MT2
ells) (Mascola et al., 1993) are typically about five times
igher than our EIAV values. Therefore, in light of the
ifference in viruses and assay systems, it is not possi-
le a priori to determine an “expected” threshold or level
f in vitro serum enhancement in the EIAV system.
ather, by allowing the data to speak for itself, we can
onclude in the EIAV system that an average in vitro
erum enhancement level of 1.5 is associated with an
verage 100-fold increase in viremia in rgp90-vaccinated
onies at only 21 days post-challenge (Raabe et al.,
998a). These observations suggest to us that even rel-
tively low levels of specific in vitro serum enhancement
an have profound in vivo effects on levels of virus
eplication and severity of disease.
A second concern about the EIAV in vitro enhance-
ent assay is the extent of variation observed in inde-
endent assays of the same immune serum sample. We
ttribute this level of variation to two factors. The first
ariable appears to be intrinsic differences in the primary
acophage cultures produced for different assays. Al-
hough all macrophages used in these assays were
roduced by standard procedures from a single donor
ony to minimize variation in the target cells, it is possi-
le that small differences in the product macrophage
ould influence virus replication and observed enhance-
ent levels. A second probable source of observed vari-
tion is that the in vitro assay is measuring relatively
mall differences in levels of virus replication, such that
ariations of 10% in measurements of virus production
ause significant variations in the final enhancementndex. To account for this variability, we repeated the in titro enhancement assays of each serum sample in four
ndependent assays and subjected the data to rigorous
nalyses. Thus, we are confident that the in vitro en-
ancement data are as accurate as possible at this time
or the EIAV/equine macrophage system.
In light of the variety of specific and nonspecific mecha-
isms reported for in vitro serum enhancement of virus
eplication, we utilized the macrophage culture system to
xamine the roles of serum immunoglobulin and comple-
ent in the enhancement of EIAV replication in vitro. The
ata presented here demonstrated that virus-specific anti-
odies, but not complement, were involved in the enhance-
ent of virus replication in equine macrophages, indicating
omplement-independent ADE as the mechanism of in vitro
erum enhancement. In contrast, both complement-depen-
ent and complement-independent ADE have been ob-
erved in vitro for HIV-1 (Homsy et al., 1988, 1989; Robinson
t al., 1988, 1990b; Takeda et al., 1988).
While the current in vitro enhancement data implicate
irus-specific antibodies in vaccine enhancement in vivo,
he survey of immune serum samples from a panel of rgp90
accinated ponies did not establish a definitive correlation
etween the levels of in vitro enhancement and the pres-
nce or severity of in vivo vaccine enhancement as deter-
ined by levels of viremia and severity of disease. The lack
f an evident correlation of in vitro enhancement levels with
n vivo enhancement probably is indicative of the fact that
he latter is a complex phenomenon that depends on a
umber of parameters, including important genetic variabil-
ties among the outbred ponies used in these studies. In
ddition, it is possible that other serum factors, such as
ytokines or chemokines, could influence observed in vivo
nhancement levels as important mediators of immune
esponses, virus replication, and pathogenesis (Crawford
t al., 1996; Tornquist et al., 1997). Studies are currently in
rogress to evaluate the potential role of selected cytokines
nd chemokines in EIAV disease and vaccine enhancement.
Although the in vitro enhancement assay did not cor-
elate with the extent of enhancement among rgp90
mmunized ponies, the data did demonstrate that the
gp90 immune serum had a higher propensity to in-
rease EIAV replication in vitro compared to immune
erum samples from ponies immunized with a protective
LL-gp) envelope subunit vaccine. As neither serum con-
ained detectable serum neutralizing activity in macro-
hage assays, the difference in the levels of virus repli-
ation cannot be attributed to the presence or absence
f neutralizing antibodies. Rather the distinct differences
n serum enhancement by the rgp90 and LL-gp immune
era appear to reflect important differences in the enve-
ope-specific antibodies elicited by these respective en-
elope protein immunogens. Thus, it will be important to
xamine in more detail the nature of the envelope-spe-
ific antibodies associated with protective and enhanc-
ng vaccine immunity by using novel serological assays
o discriminate between these antibody populations.
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425EQUINE INFECTIOUS ANEMIA VIRUS ENHANCEMENTThe potential implications of these EIAV in vitro en-
ancement assays for AIDS vaccine development will
ikely depend on the perspective of the individual. It is
lways difficult to extrapolate results between different
entiviruses, and the use of animal models (including SIV)
or AIDS vaccine development has not provided the “gold
tandard” that was envisioned 10 years ago. However,
he EIAV system, more than any other lentivirus, has
learly demonstrated that virus-specific immune re-
ponses to candidate vaccines are a double-edged
word that can either provide apparently sterile protec-
ion from virus challenge or produce fatal enhancement
f virus replication and disease upon virus exposure. The
urrent studies indicate that in vitro serum enhancement
ssays are at best an insensitive indicator of in vivo
mmune enhancement. Therefore, it is possible that the
ow levels of in vitro serum enhancement observed in
IV-1-infected individuals and SIV-infected monkeys may
ave a larger impact in vivo than previously recognized.
t a minimum, the EIAV studies described here focus
ttention on the need to reevaluate the assessment of
DE in human AIDS vaccine trials and to reinvigorate
fforts to understand the nature of enhancing immune
esponses and enhancing antigenic determinants of the
iral envelope proteins. The results of such studies will
e important in designing vaccine immunogens to mini-
ize the potential for vaccine enhancement by candidate
IDS vaccines and in designing more reliable in vitro
ssays as correlates of in vivo immune enhancement.
MATERIALS AND METHODS
Virus culture. The virus stock used in this study was
he pathogenic PV strain of EIAV (EIAVPV) (Rwambo et al.,
990). The EIAVPV was propagated in primary FEK cells
hat were prepared and cultured in minimal essential
edium (MEM) (Gibco BRL) supplemented with 10% fetal
ovine serum, 100 IU of penicillin per milliliter and 100
g of streptomycin per milliliter at 37°C with humid air
nd 5–7% CO2. Cell-free supernatants were aliquoted
nd stored at 270°C. The infectious virus titers were
etermined using an infectious center assay in FEK cells
Hammond et al., 1997).
Cells. The isolation of MDM cells from whole blood was
erformed as described previously (Raabe et al., 1998b).
or immediate use, freshly isolated cells were resuspended
n 0.5 ml minimal essential medium Alpha (MEMa) contain-
ng L-glutamine supplemented with 10% adult equine serum
Hyclone), 100 IU of penicillin per milliliter, 100 mg of strep-
omycin per milliliter, and 10 mM HEPES (MEMa 1 10%
S), seeded directly into 48-well tissue culture plates at a
ensity of 1 3 105 cells per well, and incubated at 37°C with
umid air and 6% CO2. Frozen cells were thawed quickly
nd added slowly to cold MEMa medium supplemented
ith 50% adult bovine serum (Hyclone), 100 IU of penicillin
er milliliter, 100 mg of streptomycin per milliliter, and 10 iM HEPES (MEMa 1 50% ABS). Following centrifugation
t 200 g for 10 min the cells were resuspended in MEMa 1
0% ABS and seeded as described above. Following 1 day
n culture, the MEMa 1 50% ABS medium was removed
nd replaced with MEMa 1 10% HS medium. MDM cells
ere utilized in infection studies within the first 3 days of
ulture.
Optimized EIAV in vitro enhancement assay. To evalu-
te a serum’s ability to enhance EIAV infectivity in vitro,
n appropriate dilution of the test serum was prepared in
00 ml of MEMa containing 100 IU of penicillin per
illiliter, 100 mg of streptomycin per milliliter, and 10 mM
EPES. The diluted serum samples were then incubated
or 1 h at 37°C with 104 infectious units of EIAVPV, and the
irus–serum mixtures were used to infect cultured mac-
ophages for 2 h at 37°C. Following the removal of the
irus–serum mixtures, 0.5 ml of MEMa 1 10% HS me-
ium was added to the macrophage cell cultures. All
ultures were then supplemented with 10 ml of the ap-
ropriate preimmune or immune serum to achieve a final
ilution of 1:50. Levels of virus replication in the cultures
ere monitored by reverse transcriptase (RT) activity in
ell supernatants collected at 5 and 7 days postinfection
dpi). Levels of ADE were defined as the ratio of the RT
ctivity produced in cell cultures infected in the presence
f immune serum compared to cell cultures infected in
he presence of autologous preimmune serum. Thus,
atios greater than 1.0 were associated with enhance-
ent of EIAV replication in vitro, while ratios less than 1.0
ndicated suppression of EIAV replication.
Microreverse transcriptase assay. The reverse tran-
criptase activity in the cell supernatants was deter-
ined using a microreverse transcriptase assay for EIAV
s described previously (Raabe et al., 1998b).
Determination of EIAV-specific antibody titers. Antibod-
es against EIAVPV determinants were identified in an ELISA
ssay using viral gp90 or rgp90 bound to microplates with
on A as described previously (Hammond et al., 1997).
Analysis of neutralizing antibodies. Serum neutralizing
ntibody titers were assessed in an indirect cell ELISA-
ased infectious center assay using FEK cells as de-
cribed previously (Hammond et al., 1997).
Ammonium sulfate precipitation of Ig from whole se-
um. Isolation of the immunoglobulin fraction from poly-
lonal immune serum was performed by saturated am-
onium sulfate (SAS) precipitation (Coligan et al., 1994).
riefly, particulates were removed from the sera by cen-
rifugation for 30 min at 13,000 rpm at 4°C. SAS was
lowly added to the serum while stirring to a 45% (vol/vol)
oncentration. Precipitation was allowed to continue
vernight at 4°C with additional stirring. On the following
ay, serum supernatants were separated from the Ig
recipitates by centrifugation for 1 h at 13,000 rpm at
°C. The isolated Ig samples were resuspended in phos-
hate-buffered saline (PBS) solution to a volume approx-mately half that of the original whole serum sample, and
t
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426 RAABE, ISSEL, AND MONTELAROhe isolated Ig and supernatant samples were dialyzed
gainst three changes of 4 liters of PBS at 4°C. Following
ialysis, the protein concentrations of the precipitated Ig
nd supernatant samples were determined using the
ommercially available Lowry-based DC protein assay
ystem (Bio-Rad Laboratories), and the presence of
eavy (55,000) and light chain (25,000) Ig was confirmed
y Western blot analysis. The precipitated Ig samples
ere then resuspended to approximate the Ig concen-
ration of the original whole serum sample, and the
eactivity of the purified Ig to native viral glycoprotein
as confirmed to be equivalent to the whole serum
ample by Con A ELISA (data not shown). Therefore,
hen evaluating the Ig samples in the EIAV in vitro
nhancement assay, concentrations equivalent to 1:5
ilutions of whole serum were utilized.
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